

## Article

# Maternal Vaccination and Neonatal Feeding Strategies Among Polish Women

Jolanta Lis-Kuberka \*  and Magdalena Orczyk-Pawiliowicz \* 

Division of Chemistry and Immunochemistry, Department of Biochemistry and Immunochemistry, Wrocław Medical University, M. Skłodowskiej-Curie 48/50, 50-369 Wrocław, Poland

\* Correspondence: jolanta.lis-kuberka@umw.edu.pl (J.L.-K.); magdalena.orczyk-pawilowicz@umw.edu.pl (M.O.-P.); Tel.: +48-71-770-32-17 (J.L.-K.); +48-71-770-30-64 (M.O.-P.)

**Abstract: Background/Objectives:** Maternal vaccination and breastfeeding are important aspects of public health that should be recommended by medical staff caring for pregnant and postpartum women. We aimed to analyze factors affecting women's likelihood of dual vaccination during pregnancy and their infant feeding strategies. **Methods:** A cross-sectional study was conducted with 953 Polish mothers. An online questionnaire was used and included questions on sociodemographic and obstetric variables, women's attitudes towards COVID-19 and influenza vaccination, and breastfeeding practices. **Results:** COVID-19 vaccination was reported by 66.0%, influenza vaccination by 18.2%, and dual vaccination by 15.6% of Polish mothers. Increasing willingness to receive vaccines was significantly associated with older maternal age, lower BMI, living in urban areas with >100,000 residents, and high levels of knowledge regarding vaccination. No significant association between dual vaccination and neonatal feeding strategy was detected. The group of exclusively breastfeeding mothers, in comparison to formula- and mixed-feeding women, was characterized by having lower pre-pregnancy BMI and previous maternal experience. **Conclusions:** Rates of vaccination against seasonal influenza and dual (influenza and COVID-19) vaccination remain low among Polish mothers. The promotion of antenatal vaccination and reliable information about short- and long-term advantages related to breastfeeding are crucial to perinatal health care for the mother–infant dyad. Young, primiparous women who are overweight or obese should be targets of preventive programs focused on the health of the mother–infant dyad.



Academic Editor: Pedro Plans-Rubió

Received: 29 January 2025

Revised: 21 March 2025

Accepted: 27 March 2025

Published: 31 March 2025

**Citation:** Lis-Kuberka, J.; Orczyk-Pawiliowicz, M. Maternal Vaccination and Neonatal Feeding Strategies Among Polish Women. *Vaccines* **2025**, *13*, 376. <https://doi.org/10.3390/vaccines13040376>

**Copyright:** © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

**Keywords:** maternal vaccination; breastfeeding; influenza and SARS-CoV-2 virus; infant's protection; feeding strategy

## 1. Introduction

Vaccination is key to primary health care and constitutes an important issue in public health. It has been reported that vaccination according to the standard recommendations allows individuals to avoid some infectious diseases and prevents approximately 2.5 million deaths yearly [1]. Health-enhancing behaviors like vaccination among mothers during pregnancy, in the perinatal period, and during lactation are particularly interesting. Antenatal vaccination induces a vaccine-specific immune response in the mothers, which includes the synthesis of specific IgG antibodies that not only protect women but also are transferred to the fetus, priming the developing fetus for postnatal life [2]. The transplacental passive transfer of IgG molecules is mediated by FcRn, which is localized in the placental syncytiotrophoblast, and this process is an important mechanism that protects the infant while his/her humoral response is inefficient [3]. The highest rate of maternal-antibody transport

is observed at 28–32 weeks of gestation [2,4]. Maternal IgG antibodies transferred during the perinatal period provide passive immunity, and they represent a powerful tool for the protection of infant after birth, especially since newborns cannot produce IgG antibodies in the first months of their life [2,4–7]. In the months after birth, there is a decrease in maternal IgG levels in the neonatal circulation, which is the result of their catabolism (in the period of physiological hypogammaglobulinemia) and occurs between months 3 and 6 of life. This period overlaps with the endogenous synthesis of IgG by the infant, which begins approximately 15 weeks after birth [5–7].

Newborns and infants have immature immune systems and are susceptible to infections in the first years of life [8–14]. In the early stage of postnatal life, infections can cause morbidity and mortality in infants and are extremely dangerous for preterm neonates. Influenza virus, respiratory syncytial virus (RSV), rhinoviruses (RVs), and human parainfluenza viruses (HPIVs) are responsible for the majority of hospitalizations of infants suffering from lower respiratory tract infections [15–20]. Moreover, due to the immaturity of their immune systems, infants may be expected to be more susceptible to infection caused by the SARS-CoV-2 virus, which is associated with the occurrence of multi-inflammatory syndrome in neonates [21,22]. To protect against infection in infants and also in mothers, vaccinations during pregnancy are recommended. The Polish Society of Gynecologists and Obstetricians recommends, during pregnancy, the administration of vaccines containing inactivated pathogens, either whole or as fragments [23–27]. The most common examples include influenza and pertussis vaccination, which represent significant breakthroughs in reducing perinatal mortality [28]. The COVID-19 pandemic introduced a third vaccine, the effectiveness and safety of which were ensured through rigorous testing criteria [23,28–31].

It has been reported that influenza/COVID-19 vaccination during pregnancy has positive outcomes for the mother–infant dyad, namely providing passive immunity to the infant before birth by transplacental transfer of vaccine-induced IgG antibodies and after delivery via the maternal milk, which contains specific antibodies (mainly S-IgA) that are transferred to the newborn/infant during breastfeeding [32–37]. Moreover, it has been reported that influenza/COVID-19 vaccination during pregnancy provides protection for women in the perinatal and postpartum period and prevents the virus's transmission from mother to infant after delivery [38]. Zaman et al. [39] reported that transferred maternal IgG antibodies specific to influenza that were induced during pregnancy remained in infants' circulation for 6 months and that a similarly high level of influenza vaccine-induced S-IgA antibodies was found in the maternal milk. Similarly, Edlow's working group [40] reported that maternal COVID-19 vaccine-induced antibodies are detected in infants in the first year of life and that perinatal COVID-19 vaccination effectively reduces the risk of occurrence of COVID-19 among the youngest members of society, namely infants less than 6 months of age [40–42]. Working groups [43–45] demonstrated that pregnant women exhibit strong immune responses to COVID-19 vaccines, which allow them to achieve antibody levels comparable to those seen in non-pregnant women of reproductive age. Lopez et al. [40] highlighted that the persistence of antibodies in infants is associated with maternal vaccine timing, placental Fc-receptor binding capabilities, and antibody subclass. Moreover, it should be pointed out that vaccination of women should be performed even for individuals who have been infected in the past because it has been reported that higher transfer of virus-specific IgG from mother to fetus is observed with infection plus vaccination [46]. Maternal vaccination plays an essential role in providing neonates with protection because influenza and COVID-19 vaccinations are not available for infants under 6 months of age [34,35,47–51].

Even though perinatal vaccinations are recommended for women during pregnancy and during breastfeeding, data regarding the impact of vaccination on the choice of feeding

strategy for neonates are limited [52,53]. It is well known that breastfeeding offers many health benefits to newborns and infants. As reported by Ladomenou et al. [54], independent of neonatal gestational age and birth weight and also the type of delivery, the frequency and duration of breastfeeding are among the main factors affecting the valuable effect of human milk. According to the World Health Organization (WHO) [55], breastfeeding exclusively for six months is considered the gold standard and leads to lower risk of infections (e.g., respiratory infection and acute otitis media) and hospital admissions in comparison to not breastfeeding [54]. Another working group [56] found that the odds of having had a disease with fever in the last two weeks were 66% lower among infants who were exclusively breastfed than among non-exclusively breastfed neonates. Moreover, exclusively breastfed infants have lower odds of having a disease with cough and diarrhea than non-exclusively breastfed infants. In light of this evidence, breastfeeding as a neonatal feeding strategy in the first months of the infant's life should be especially recommended by obstetricians and nurses taking care of women in the perinatal period. Exclusive breastfeeding for the first half year of an infant's life, with continued breastfeeding up to 2 years of age or beyond, is recommended by the WHO as the gold standard for the nutrition of newborns and infants [57] and yields substantial benefits for both infant and mother. In Poland, the breastfeeding rate reported by mothers at the beginning of lactation is quite high (97–99.4%) [58–62]. However, women who decide to continue exclusive breastfeeding up to 6 months represent only 4–22.4% of mothers [59]. It has been reported [62] that the factors most frequently associated with a mother's decision to discontinue breastfeeding are too few lactation consultants, problems with breastfeeding after returning to work, and negative attitudes towards breastfeeding in public places [62]. Moreover, it has been reported that Polish women have moderate knowledge of breastfeeding benefits and poor knowledge about correct breastfeeding attachment and positioning techniques [63–66].


Artzi-Medvedik et al. [52] identified an association between influenza vaccination during pregnancy and breastfeeding for at least three months in a population of women from the United States. On the other hand, Weston et al. [53], based on research including 18 breastfeeding mothers who received COVID-19 vaccination, highlighted that an individual woman's habitus has an impact on her knowledge level, attitudes, and beliefs and interacts with options for infant feeding and health-promoting behaviors such as vaccination. So far, the impact of dual vaccination on breastfeeding as a neonatal feeding strategy has not been analyzed. In light of the above, the primary aim of this study was to evaluate whether mothers' influenza and/or COVID-19 vaccination status was associated with their choice of infant feeding strategy in the obstetric population. The secondary objectives of this study included evaluating the knowledge level regarding maternal vaccination and the identification of factors associated with perinatal vaccination. The second part of the analysis involves the evaluation of variables associated with the choice of breastfeeding as a strategy for infant feeding. Finally, the relationship between health-enhancing behaviors such as maternal vaccination and breastfeeding was assessed. The sociodemographic and obstetric variables identified in this study will help select the most vulnerable groups of Polish women, those who should be the targets of preventive programs regarding the health of the mother–infant dyad.

## 2. Materials and Methods

### 2.1. Study Design and Participants

An anonymous survey was used to assess rates of influenza vaccination, influenza/COVID-19 (dual) vaccination, and breastfeeding among Polish women. The research was approved by the Ethics Committee at Wroclaw Medical University (No. KB-356/21). The survey was composed of the following sections: (1) maternal sociodemographic data,

(2) obstetric variables, and (3) knowledge regarding maternal vaccination and influenza and COVID-19 vaccination among Polish mothers. The primary version of the questionnaire was subjected to pilot testing. Comments and suggestions from five mothers were included in the development of the final version of the online survey. Cronbach's alpha was used for the reliability assessment of the questionnaire, and it ranged from 0.30 to 0.62. The survey was administered online (with respondents recruited via Facebook), and it targeted women who were pregnant or had recently delivered an infant. This study is a secondary analysis of data collected from previous research [67]. The total number of women recruited for the study was 1244. However, because the analysis focused on health-promoting behaviors and also examined infant feeding strategies, the analysis excluded pregnant women. Incomplete and unreliable data were excluded from the analysis. The final dataset included 953 postpartum mothers (Figure 1). This was a cross-sectional (observational) study.



**Figure 1.** Flow chart for respondents' inclusion in the study.

## 2.2. Data Source and Study Size

The survey was conducted from 15 November 2021 to 31 March 2022 among Polish women. The survey was administered using Google Forms, and potential participants were recruited for the study through parenting communities via Facebook. The data regarding COVID-19 vaccination status were expanded to include the information about influenza vaccination and data regarding feeding strategies for infants. Finally, based on sociodemographic and obstetrical data, as well as data on knowledge about vaccination, we evaluated the association of vaccination against influenza and COVID-19 with breastfeeding among Polish mothers.

To calculate the sample size (calculated using TIBCO STATISTICA ver. 13.3, StatSoft, Inc., Tulsa, OK, USA), we assumed a 95% confidence level ( $\alpha$  error of 0.5%) and a 5% loss rate. Based on the total number of births in 2021/2022 (318,000) and the level of COVID-19 vaccination of the Polish population (66.0%), the minimum required sample size was 368 subjects.

### 2.3. Quantitative and Qualitative Variables

Data on maternal age and anthropometric variables such as body weight and height were provided by the participants of the research and collected as quantitative data. In the following step of the performed analysis, maternal age was categorized into ranges of 18–25, 26–34, and  $\geq 35$  years, while pre-pregnancy body mass index (BMI) (calculated based on the data provided by respondents and classified according to the WHO guidelines [68]) data were categorized as follows: underweight ( $<18.5 \text{ kg/m}^2$ ), normal weight ( $18.50\text{--}24.9 \text{ kg/m}^2$ ), overweight ( $25.0\text{--}29.9 \text{ kg/m}^2$ ), and obese ( $\geq 30 \text{ kg/m}^2$ ).

The data regarding education level (vocational and primary, high school, university), marital status (single parent and divorced, cohabiting, married), residence (rural area, urban  $<10,000$  residents, urban  $>100,000$  residents, urban  $10,000\text{--}100,000$  residents), obstetric data (mode of delivery: vaginal birth, elective cesarean section, emergency cesarean section), maternal experience (no maternal experience, 1 child, 2 children,  $\geq 3$  children), and neonatal feeding strategies (breastfeeding, mixed feeding, formula feeding) were classified as qualitative variables.

The assessment of the mother's knowledge level concerning perinatal vaccination was estimated based on the following questions: "Can the SARS-CoV-2 virus be transmitted via human milk?"; "Can breastfeeding mothers who received COVID-19 vaccination reduce the risk of this disease in their child?"; "Can COVID-19 vaccine-induced humoral immunity be transferred by the placenta to the fetus?"; "Can COVID-19 vaccine-induced humoral immunity be transferred to infants via breast milk?".

The respondents could answer "Yes", "No", or "I do not know". The maternal knowledge score was computed as follows: a correct response scored +1, no answer or "I do not know" scored 0, and an incorrect response scored  $-1$ . The details concerning the assessment of maternal knowledge levels were adapted from Ramli et al. [69]. The mother's knowledge level regarding perinatal vaccination was categorized as follows: score 4 out of 4 (100%)—detailed knowledge, score 2 or 3 out of 4 (50–75%)—moderate knowledge, and score lower than 2 out of 4 ( $<50\%$ )—poor knowledge.

### 2.4. Statistical Analysis

All data, including continuous and nominal (categorical) variables, were analyzed using TIBCO STATISTICA, version 13.3 (StatSoft, Inc., Tulsa, OK, USA). Means and standard deviations (the mean  $\pm$  SD) and median and 25–75% interquartile range were reported to describe continuous variables (age and BMI of respondents) and frequencies and percentages (% (n/N)) were reported to describe categorical variables. To compare groups, the chi-square test was used. To test the research questions, multiple comparison tests (Bonferroni) for related samples were used.

The variables (age, BMI, residence, education, marital status, and mother's level of knowledge about maternal vaccination) were selected based on the result of the chi-square test and then subjected to univariate analysis.

Multivariate logistic regression was used to determine which of the predictors of positive health-related behaviors, such as breastfeeding, among Polish mothers yielded  $p < 0.05$  using the odds ratio (OR). In the initial model, considering a significance level of 0.1, the following variables were selected for inclusion in the multivariate logistic regression model: BMI, level of knowledge about maternal vaccination, influenza vaccination, and dual vaccination. An analysis of linearity and additivity of the relationship between variables was performed. As a method for scoring and selecting a model, the best subset (all effects) was used. The confidence level was set at 95%, with statistical significance defined as  $p < 0.05$ . For multivariate logistic regression, the following parameters were obtained:  $\beta$  coefficient  $p < 0.05$ , and for Hosmer–Lemeshow's test,  $p = 0.68$ .

### 3. Results

#### 3.1. Sociodemographic and Obstetric Data of Respondents

The mean age of the respondents was  $31.0 \pm 4.4$  years, with a range of 18–46 years. Most of the participants (623/953; 65.4%) had a normal pre-pregnancy BMI, and women who were underweight, overweight, or obese constituted 6.4% (61/953), 18.6% (177/953) and 9.7% (92/953) of the sample, respectively. Mothers living in urban areas with a population >100,000 (460/953; 48.3%) constituted the majority of the group, while 20.6% of respondents reported living in cities with a population of 10,000–100,000 residents and 24.2% of women reported living in a rural area. Higher education was reported by 79.2% of participants (755/953). Married women constituted 82.1% of participants (782/953), while single parenthood and divorced status were reported by 1.9% of the participants (18/953) (Table 1).

**Table 1.** General characteristics of participants.

| Data                                 | n/N                                 | %                |
|--------------------------------------|-------------------------------------|------------------|
| Age (years)                          | Mean $\pm$ SD                       | $31.0 \pm 4.4$   |
|                                      | Median (interquartile range 25–75%) | 31.0 (28.0–34.0) |
|                                      | 18–25                               | 92/953           |
|                                      | 26–34                               | 649/953          |
|                                      | $\geq 35$                           | 212/953          |
| Pre-pregnancy BMI, kg/m <sup>2</sup> | Mean $\pm$ SD                       | $23.5 \pm 4.3$   |
|                                      | Median (interquartile range 25–75%) | 22.5 (20.4–25.5) |
|                                      | Underweight (<18.5)                 | 61/953           |
|                                      | Normal weight (18.5–24.9)           | 623/953          |
|                                      | Overweight (25–29.9)                | 177/953          |
| Residence                            | Obesity ( $\geq 30$ )               | 92/953           |
|                                      | Urban, >100,000 residents           | 460/953          |
|                                      | Urban, 10,000–100,000 residents     | 196/953          |
|                                      | Urban, <10,000 residents            | 66/953           |
| Education                            | Rural                               | 231/953          |
|                                      | Vocational and primary              | 23/953           |
|                                      | High school                         | 175/953          |
|                                      | University                          | 755/953          |
| Marital status                       | Married                             | 782/953          |
|                                      | Cohabiting                          | 153/953          |
|                                      | Single parent and divorced          | 18/953           |
| Mode of delivery                     | Vaginal birth                       | 532/953          |
|                                      | Elective caesarean section          | 219/953          |
|                                      | Emergency caesarean section         | 202/953          |
| Maternal experience                  | 0                                   | 92/953           |
|                                      | 1                                   | 483/953          |
|                                      | 2                                   | 268/953          |
|                                      | $\geq 3$                            | 110/953          |



**Table 1.** *Cont.*

| Data                      |                 | n/N     | %    |
|---------------------------|-----------------|---------|------|
| Neonatal feeding strategy | Breastfeeding   | 764/953 | 80.2 |
|                           | Mixed feeding   | 103/953 | 10.8 |
|                           | Formula feeding | 86/953  | 9.0  |
| COVID-19 vaccination      | Yes             | 629/953 | 66.0 |
|                           | No              | 324/953 | 34.0 |
| Influenza vaccination     | Yes             | 173/953 | 18.2 |
|                           | No              | 780/953 | 81.8 |
| Dual vaccination          | Yes             | 149/953 | 15.6 |
|                           | No              | 804/953 | 84.4 |

The table shows the percentage of respondents in the given subgroup (n) in relation to all respondents (N) for whom the specific information was available.

In the analyzed obstetric population, the majority, 55.8% (532/953), reported vaginal delivery (Table 1). Mothers with prior maternal experience constituted more than 90.3% (861/953) of respondents (Table 1). Further, 80.2% of respondents reported breastfeeding as a neonatal feeding approach, while formula and mixed feeding were reported by 9.0% and 10.8%, respectively. Additionally, 66% of respondents reported COVID-19 vaccination, 18.2% reported influenza vaccination, and only 15.6% reported dual vaccination.

### 3.2. Sociodemographic and Obstetric Data of Respondents in Relation to Vaccination Status

In the present study, 66.0% (623/953) and 18.2% (173/953) of mothers reported that they had received the COVID-19 and influenza vaccines, respectively. Dual vaccination was reported by 15.6% (149/953) of respondents (Table 1).

The analysis of sociodemographic data in relation to maternal vaccination status showed that the women most likely to have been vaccinated were 26–34 years old, had higher education, and lived in urban areas with > 100,000 residents. For dual vaccination and COVID-19 vaccination, significant differences in categorical data such as age, residence, and education were noted. In contrast, for mothers who had received the influenza vaccine, significant differences in pre-pregnancy BMI and residence were recorded (Table 2). The Bonferroni multiple-comparisons test was performed to determine which variables significantly differed from each other. The results are displayed in Supplementary Materials Table S1. The results showed that rates of dual/COVID-19 vaccination significantly differed with respect to age in the following comparisons: 18–25 vs. 26–34 ( $p$ -value from 0.00004 to 0.04) and 18–25 vs.  $\geq 35$  ( $p$ -value from 0.00002 to 0.04). Moreover, rates of influenza vaccination and/or COVID-19 vaccination significantly differed with respect to place of residence, specifically for urban areas with >100,000 residents vs. <10,000 residents ( $p < 0.02$  for dual and  $p < 0.008$  for COVID-19 vaccination), urban areas with >100,000 vs. <10,000 residents ( $p < 0.0004$  for COVID-19 vaccination), and urban areas with >100,000 residents vs. rural areas ( $p < 0.0008$  for dual and  $p < 0.000001$  for COVID-19 vaccination). Significant differences were also seen with respect to educational level in the comparison of high school vs. university education ( $p < 0.007$  for dual vaccination and  $p < 0.00001$  for COVID-19 vaccination).

**Table 2.** Sociodemographics and health-enhancing behaviors of respondents in relation to maternal vaccination status.

| Data                                 |                                     | Dual Vaccination    |                     | Chi <sup>2</sup><br><i>p</i> -Value           | COVID-19 Vaccination |                     | Chi <sup>2</sup><br><i>p</i> -Value           | Influenza Vaccination |                     | Chi <sup>2</sup><br><i>p</i> -Value        |
|--------------------------------------|-------------------------------------|---------------------|---------------------|---|----------------------|---------------------|---|-----------------------|---------------------|--|
|                                      |                                     | Yes<br>N = 149      | No<br>N = 804       |   | Yes<br>N = 629       | No<br>N = 324       |   | Yes<br>N = 173        | No<br>N = 780       |  |
| Age (years)                          | Mean ± SD                           | 32.01 ± 3.94        | 30.8 ± 4.4          | Chi <sup>2</sup> = 6.7<br><i>p</i> < 0.04     | 31.5 ± 4.2           | 30.0 ± 4.6          | Chi <sup>2</sup> = 23.1<br><i>p</i> < 0.00009 | 31.6 ± 4.2            | 30.8 ± 4.4          | Chi <sup>2</sup> = 3.0<br><i>p</i> < 0.3   |
|                                      | Median (interquartile range 25–75%) | 32.0<br>(29.0–34.0) | 30.0<br>(28.0–34.0) |   | 31.0<br>(29.0–34.0)  | 29.0<br>(26.0–33.0) |   | 31.0<br>(29.0–34.0)   | 30.0<br>(28.0–34.0) |  |
|                                      | 18–25                               | 6.3% (6/953)        | 9.1% (87/953)       |   | 4.3% (41/953)        | 5.5% (52/953)       |   | 1.2% (11/953)         | 8.6% (82/953)       |  |
|                                      | 26–34                               | 11.1%<br>(106/953)  | 56.9%<br>(542/953)  |   | 45.9%<br>(437/953)   | 22.1%<br>(211/953)  |   | 12.6%<br>(120/953)    | 55.4%<br>(528/953)  |  |
|                                      | ≥35                                 | 3.9% (37/953)       | 18.4%<br>(175/953)  |   | 15.8%<br>(151/953)   | 6.4% (61/953)       |   | 4.4% (42/953)         | 17.8%<br>(170/953)  |  |
| Pre-pregnancy BMI, kg/m <sup>2</sup> | Mean ± SD                           | 22.59 ± 3.75        | 23.6 ± 4.3          | Chi <sup>2</sup> = 8.0<br><i>p</i> < 0.05     | 23.7 ± 4.5           | 23.1 ± 3.9          | Chi <sup>2</sup> = 0.2<br><i>p</i> < 0.9      | 22.6 ± 3.7            | 23.6 ± 4.4          | Chi <sup>2</sup> = 8.6<br><i>p</i> < 0.04  |
|                                      | Median (interquartile range 25–75%) | 21.8<br>(20.2–24.1) | 22.7<br>(20.5–25.7) |   | 22.7<br>(20.5–25.7)  | 22.5<br>(20.3–25.1) |   | 22.0<br>(20.2–24.2)   | 22.8<br>(20.5–25.7) |  |
|                                      | Underweight (<18.5)                 | 1.2% (11/953)       | 5.6% (53/953)       |   | 4.4% (42/953)        | 2.3% (22/953)       |   | 1.4% (13/953)         | 5.4% (51/953)       |  |
|                                      | Normal weight (18.5–24.9)           | 11.5%<br>(110/953)  | 53.9%<br>(514/953)  |   | 42.6%<br>(406/953)   | 22.9%<br>(218/953)  |   | 13.3%<br>(127/953)    | 52.2%<br>(497/953)  |  |
|                                      | Overweight (25–29.9)                | 2.2% (21/953)       | 16.1%<br>(153/953)  |   | 11.9%<br>(113/953)   | 6.4% (61/953)       |   | 2.5% (24/953)         | 15.7%<br>(150/953)  |  |
| Residence                            | Obesity (≥30)                       | 0.7% (7/953)        | 8.8% (84/953)       | Chi <sup>2</sup> = 21.9<br><i>p</i> < 0.00007 | 9.3% (89/953)        | 2.4% (23/953)       | Chi <sup>2</sup> = 21.5<br><i>p</i> < 0.0003  | 0.9% (9/953)          | 8.6% (82/953)       | Chi <sup>2</sup> = 10.3<br><i>p</i> < 0.02 |
|                                      | Urban, above 100,000 residents      | 10.3% (98/953)      | 40.0%<br>(362/953)  |   | 36.9%<br>(352/953)   | 11.3%<br>(108/953)  |   | 10.7%<br>(102/953)    | 37.6%<br>(358/953)  |  |
|                                      | Urban, 10,000–100,000 residents     | 2.3% (22/953)       | 18.3%<br>(174/953)  |   | 13.2%<br>(126/953)   | 7.3% (70/953)       |   | 3.1% (30/953)         | 17.4%<br>(166/953)  |  |
|                                      | Urban, <10,000 residents            | 7.3% (7/953)        | 6.2% (59/953)       |   | 3.7% (35/953)        | 3.2% (31/953)       |   | 1.2% (11/953)         | 5.8% (55/953)       |  |
|                                      | Rural                               | 2.3% (22/953)       | 21.9%<br>(209/953)  |   | 12.2%<br>(116/953)   | 12.1%<br>(115/953)  |   | 3.1% (30/953)         | 21.1%<br>(201/953)  |  |



Table 2. Cont.

| Data                |                          | Dual Vaccination |                 | Chi <sup>2</sup><br><i>p</i> -Value        | COVID-19 Vaccination |                 | Chi <sup>2</sup><br><i>p</i> -Value           | Influenza Vaccination |                 | Chi <sup>2</sup><br><i>p</i> -Value      |
|---------------------|--------------------------|------------------|-----------------|--|----------------------|-----------------|---|-----------------------|-----------------|--|
|                     |                          | Yes<br>N = 149   | No<br>N = 804   |  | Yes<br>N = 629       | No<br>N = 324   |   | Yes<br>N = 173        | No<br>N = 780   |  |
| Education           | Vocational and primary   | 4.2% (4/953)     | 2.0% (19/953)   | Chi <sup>2</sup> = 9.5<br><i>p</i> < 0.009 | 1.0% (10/953)        | 1.4% (13/953)   | Chi <sup>2</sup> = 36.4<br><i>p</i> < 0.00002 | 0.5% (5/953)          | 1.9% (18/953)   | Chi <sup>2</sup> = 3.7<br><i>p</i> < 0.2 |
|                     | High school              | 1.5% (14/953)    | 16.9% (161/953) |  | 8.9% (85/953)        | 9.4% (90/953)   |   | 2.4% (23/953)         | 15.9% (152/953) |  |
|                     | University               | 13.7% (131/953)  | 65.5% (624/953) |  | 56.0% (534/953)      | 23.2% (221/953) |   | 15.2% (145/953)       | 64.0% (610/953) |  |
| Marital status      | Married                  | 13.6% (130/953)  | 68.4% (652/953) | Chi <sup>2</sup> = 3.2<br><i>p</i> < 0.2   | 56.5% (538/953)      | 25.6% (244/953) | Chi <sup>2</sup> = 15.9<br><i>p</i> < 0.0004  | 14.9% (142/953)       | 67.2% (640/953) | Chi <sup>2</sup> = 3.1<br><i>p</i> < 0.2 |
|                     | Cohabiting               | 1.8% (17/953)    | 14.3% (136/953) |  | 8.7% (83/953)        | 7.3% (70/953)   |   | 2.6% (25/953)         | 13.4% (128/953) |  |
|                     | Single parent & divorced | 0.2% (2/953)     | 1.7% (16/953)   |  | 0.8% (8/953)         | 1.0% (10/953)   |   | 0.6% (6/953)          | 1.3% (12/953)   |  |
| Mode of delivery    | Vaginal birth            | 8.8% (84/953)    | 47.1% (449/953) | Chi <sup>2</sup> = 0.3<br><i>p</i> < 0.9   | 35.3% (336/953)      | 20.7% (197/953) | Chi <sup>2</sup> = 5.7<br><i>p</i> < 0.06     | 9.9% (95/953)         | 46.0% (438/953) | Chi <sup>2</sup> = 0.3<br><i>p</i> < 0.9 |
|                     | Elective c-section       | 3.8% (36/953)    | 19.2% (183/953) |  | 15.2% (145/953)      | 5.9% (56/953)   |   | 4.1% (39/953)         | 17.0% (162/953) |  |
|                     | Emergency c-section      | 3.0% (29/953)    | 18.0% (172/953) |  | 15.5% (148/953)      | 7.5% (71/953)   |   | 4.1% (39/953)         | 18.9% (180/953) |  |
| Maternal experience | 0                        | 1.9% (18/953)    | 7.8% (74/953)   | Chi <sup>2</sup> = 7.1<br><i>p</i> < 0.2   | 7.0% (67/953)        | 2.6% (25/953)   | Chi <sup>2</sup> = 4.8<br><i>p</i> < 0.4      | 2.1% (20/953)         | 7.6% (72/953)   | Chi <sup>2</sup> = 5.6<br><i>p</i> < 0.3 |
|                     | 1                        | 7.2% (69/953)    | 43.5% (415/953) |  | 33.2% (316/953)      | 17.6% (168/953) |   | 8.4% (80/953)         | 42.4% (404/953) |  |
|                     | 2                        | 5.4% (51/953)    | 22.7% (216/953) |  | 19.0% (181/953)      | 9.0% (86/953)   |   | 6.1% (58/953)         | 21.9% (209/953) |  |
|                     | 3                        | 1.1% (11/953)    | 10.4% (99/953)  |  | 6.8% (65/953)        | 4.8% (45/953)   |   | 1.5% (15/953)         | 9.9% (95/953)   |  |

Table 2. Cont.

| Data  |          | Dual Vaccination |                 | Chi <sup>2</sup><br><i>p</i> -Value          | COVID-19 Vaccination |                 | Chi <sup>2</sup><br><i>p</i> -Value           | Influenza Vaccination |                 | Chi <sup>2</sup><br><i>p</i> -Value           |
|---|----------|------------------|-----------------|--|----------------------|-----------------|---|-----------------------|-----------------|---|
|   |          | Yes<br>N = 149   | No<br>N = 804   |  | Yes<br>N = 629       | No<br>N = 324   |   | Yes<br>N = 173        | No<br>N = 780   |   |
| Knowledge level regarding perinatal vaccination | Poor     | 3.4% (32/953)    | 40.9% (390/953) | Chi <sup>2</sup> = 37.3<br><i>p</i> < 0.0008 | 17.7% (169/953)      | 28.0% (267/953) | Chi <sup>2</sup> = 266.7<br><i>p</i> < 0.0002 | 5.4% (51/953)         | 40.4% (385/953) | Chi <sup>2</sup> = 22.8<br><i>p</i> < 0.00002 |
|   | Moderate | 3.3% (31/953)    | 11.4% (109/953) |  | 11.9% (113/0953)     | 2.0% (19/953)   |   | 3.5% (33/953)         | 10.4% (99/953)  |   |
|   | Detailed | 9.0% (86/953)    | 32.0% (305/953) |  | 36.4% (347/953)      | 4.0% (38/953)   |   | 9.3% (89/953)         | 31.1% (296/953) |   |

c-section—caesarean section.

Regardless of the type of vaccination, significant differences in level of knowledge about maternal vaccination (dual vaccination  $p < 0.0008$ , COVID-19 vaccination  $p < 0.0002$ , and influenza vaccination  $p < 0.00002$ ) were noted among mothers (Table 2). On the other hand, the analysis of obstetric data in relation to vaccination status showed no significant differences in type of delivery ( $p < 0.9$ ) (Table 2). The results of the Bonferroni multiple-comparisons test showed that rates of influenza vaccination and/or COVID-19 vaccination significantly differed with respect to women's knowledge levels in the following comparisons: detailed vs. poor knowledge ( $p$ -value from  $<0.00001$  to  $0.0005$ ) and moderate vs. poor knowledge ( $p$ -value from  $<0.00001$  to  $0.0006$ ) (Supplementary Materials Table S1).

### 3.3. Sociodemographic and Obstetric Data of Respondents in Relation to Neonatal Feeding Patterns

In the present study, 80.2% (764/953) of the mothers reported breastfeeding, while the mixed and formula-feeding strategies were reported by 10.8% (103/953) and 9.0% (86/953), respectively (Table 1). The stratified analysis of sociodemographic and obstetric data of respondents in relation to neonatal feeding revealed significant differences for the following variables: maternal pre-pregnancy BMI ( $p < 0.006$ ), prior experience of motherhood ( $p < 0.0001$ ), and level of knowledge about maternal vaccination ( $p < 0.03$ ) (Table 3). In contrast, the respondents' age, place of residence, education, marital status, and obstetric variables, and status with regard to COVID-19 vaccination, influenza vaccination, or dual vaccination did not show significant differences between mothers in relation to neonatal feeding strategy (Table 3).

The Bonferroni multiple-comparisons test was performed to determine which variables significantly differed from each other. The results are displayed in Supplementary Materials Table S2. The results showed that neonatal feeding strategy significantly differed with respect to BMI in the comparisons normal weight vs. overweight ( $p < 0.002$ ) and overweight vs. obese ( $p < 0.003$ ), and with respect to maternal experience in the following comparisons: no maternal experience (0) vs. 1 child ( $p < 0.0002$ ), no maternal experience (0) vs. 2 children ( $p < 0.02$ ), no maternal experience (0) vs.  $\geq 3$  children ( $p < 0.012$ ).

### 3.4. Respondents' Sociodemographics and Obstetric Data in Relation to Maternal Experience

In the present study, 90.3% (861/953) of the women reported previous maternal experience. The percentages of women with one, two, and three or more offspring were 50.7% (483/953), 28.1% (268/953), and 11.5% (110/953), respectively (Table 1). The stratified analysis of respondents' sociodemographic and obstetric data in relation to maternal experience revealed significant differences among analyzed groups for the following variables: age ( $p < 0.0001$ ), place of residence ( $p < 0.006$ ), education ( $p < 0.0001$ ), marital status ( $p < 0.008$ ), and mode of delivery ( $p < 0.0001$ ) (Table 4). In contrast, the respondents' pre-pregnancy BMIs, levels of knowledge about maternal vaccination, and rates of COVID-19 vaccination, influenza vaccination, or dual vaccination did not show significant differences among analyzed subgroups in relation to maternal experience (Table 4).

The Bonferroni multiple-comparisons test was performed to determine which variables significantly differed from each other. The results are displayed in Supplementary Materials Table S3. The results showed that maternal experience significantly differed with respect to age in the comparisons between those aged 18–25 vs. 26–34 ( $p < 0.0004$ ), 18–25 vs.  $\geq 35$  ( $p < 0.00001$ ), and 26–34 vs.  $\geq 35$  ( $p < 0.00001$ ); with respect to place of residence in the comparison  $>100,000$  residents vs. rural areas ( $p < 0.042$ ); with respect to education in the comparisons vocational/primary vs. university ( $p < 0.048$ ) and high school vs. university ( $p < 0.00005$ ); and with respect to mode of delivery in all analyzed categories ( $p$ -values from  $<0.00001$  to  $0.01$ ) (Supplementary Materials Table S3).

**Table 3.** Sociodemographic and obstetric variables and health-enhancing behaviors in relation to neonatal feeding strategy.

| Data                                 |                                     | Breastfeeding<br>% (n/N) | Mixed Feeding<br>% (n/N) | Formula Feeding<br>% (n/N) | Chi <sup>2</sup> Test<br>p-Value      |
|--------------------------------------|-------------------------------------|--------------------------|--------------------------|----------------------------|---------------------------------------|
| Age (years)                          | Mean $\pm$ SD                       | 31.0 $\pm$ 4.4           | 31.1 $\pm$ 4.4           | 30.23 $\pm$ 4.6            | Chi <sup>2</sup> = 4.9<br>p < 0.29    |
|                                      | Median (interquartile range 25–75%) | 31.0 (28.0–34.0)         | 30.0 (28.0–34.0)         | 31.00 (27.0–33.0)          |                                       |
|                                      | 18–25                               | 10.0% (76/764)           | 6.8% (7/103)             | 11.6% (10/86)              |                                       |
|                                      | 26–34                               | 67.0% (512/764)          | 70.0% (72/103)           | 74.4% (64/86)              |                                       |
|                                      | $\geq 35$                           | 23.0% (176/764)          | 23.3% (24/103)           | 14.0% (12/86)              |                                       |
| Pre-pregnancy BMI, kg/m <sup>2</sup> | Mean $\pm$ SD                       | 23.3 $\pm$ 4.1           | 23.7 $\pm$ 4.2           | 24.7 $\pm$ 5.6             | Chi <sup>2</sup> = 23.3<br>p < 0.0006 |
|                                      | Median (interquartile range 25–75%) | 22.5 (20.3–25.3)         | 22.8 (20.8–26.0)         | 22.7 (20.5–27.3)           |                                       |
|                                      | Underweight (<18.5)                 | 6.5% (50/764)            | 8.7% (9/103)             | 5.8% (5/86)                |                                       |
|                                      | Normal weight (18.5–24.9)           | 67.1% (513/764)          | 60.2% (62/103)           | 57.0% (49/86)              |                                       |
|                                      | Overweight (25–29.9)                | 7.8% (60/764)            | 20.4% (21/103)           | 14.0% (12/86)              |                                       |
|                                      | Obesity ( $\geq 30$ )               | 18.5% (141/764)          | 10.7% (11/103)           | 23.3% (20/86)              |                                       |
| Residence                            | Urban, above 100,000 residents      | 48.2% (368/764)          | 54.4% (56/103)           | 41.9% (36/86)              | Chi <sup>2</sup> = 4.2<br>p < 0.65    |
|                                      | Urban, 10,000–100,000 residents     | 20.5% (157/764)          | 18.4% (19/103)           | 23.3% (20/86)              |                                       |
|                                      | Urban, <10,000 residents            | 6.5% (50/764)            | 7.8% (8/103)             | 9.3% (8/86)                |                                       |
|                                      | Rural                               | 24.7% (189/764)          | 19.4% (20/103)           | 25.6% (22/86)              |                                       |
| Education                            | Vocational and primary              | 2.5% (19/764)            | 1.0% (1/103)             | 3.5% (3/86)                | Chi <sup>2</sup> = 6.4<br>p < 0.17    |
|                                      | High school                         | 17.0% (130/764)          | 22.3% (23/103)           | 25.6% (22/86)              |                                       |
|                                      | University                          | 80.5% (615/764)          | 76.7% (79/103)           | 70.9% (61/86)              |                                       |
| Marital status                       | Married                             | 82.9% (633/764)          | 80.6% (83/103)           | 76.7% (66/86)              | Chi <sup>2</sup> = 7.3<br>p < 0.12    |
|                                      | Cohabiting                          | 15.3% (117/764)          | 15.5% (16/103)           | 23.3% (20/86)              |                                       |
|                                      | Single parent & divorced            | 1.8% (14/764)            | 3.9% (4/103)             | 0% (0/86)                  |                                       |
| Mode of delivery                     | Vaginal birth                       | 57.6% (440/764)          | 50.0% (51/103)           | 48.8% (42/86)              | Chi <sup>2</sup> = 4.6<br>p < 0.34    |
|                                      | Elective c-section                  | 21.9% (167/764)          | 27.2% (28/103)           | 27.9% (24/86)              |                                       |
|                                      | Emergency c-section                 | 20.5% (157/764)          | 23.3% (24/103)           | 23.3% (20/86)              |                                       |

Table 3. Cont.

| Data  |          | Breastfeeding<br>% (n/N) | Mixed Feeding<br>% (n/N) | Formula Feeding<br>% (n/N) | Chi <sup>2</sup> Test<br>p-Value      |
|---|----------|--------------------------|--------------------------|----------------------------|---------------------------------------|
| Maternal experience                               | 0        | 7.7% (59/764)            | 22.3% (23/103)           | 11.6% (10/86)              | Chi <sup>2</sup> = 30.1<br>p < 0.0001 |
|   | 1        | 51.2% (391/764)          | 40.8% (42/103)           | 59.3% (51/86)              |                                       |
|   | 2        | 28.5% (218/764)          | 32.0% (33/103)           | 18.6% (16/86)              |                                       |
|   | ≥3       | 12.6% (96/764)           | 4.8% (5/103)             | 10.5% (9/86)               |                                       |
| Knowledge level regarding<br>maternal vaccination | Poor     | 42.0% (321/764)          | 49.5% (51/103)           | 58.1% (50/86)              | Chi <sup>2</sup> = 11.0<br>p < 0.03   |
|   | Moderate | 15.6% (119/764)          | 9.7% (10/103)            | 12.8% (11/86)              |                                       |
|   | Detailed | 42.4% (324/764)          | 40.8% (42/103)           | 29.1% (25/86)              |                                       |
| COVID-19 vaccination                              | Yes      | 66.5% (508/764)          | 67.0% (69/103)           | 60.5% (52/86)              | Chi <sup>2</sup> = 1.3<br>p < 0.53    |
|   | No       | 33.5% (256/764)          | 33.0% (34/103)           | 39.5% (34/86)              |                                       |
| Influenza vaccination                             | Yes      | 19.2% (147/764)          | 14.6% (15/103)           | 12.8% (11/86)              | Chi <sup>2</sup> = 3.2<br>p < 0.21    |
|   | No       | 80.8% (617/764)          | 85.4% (88/103)           | 87.2% (75/86)              |                                       |
| Dual vaccination                                  | Yes      | 16.6% (127/764)          | 12.6% (13/103)           | 10.5% (9/86)               | Chi <sup>2</sup> = 3.0<br>p < 0.22    |
|   | No       | 83.4% (637/764)          | 87.4% (90/103)           | 89.5% (77/86)              |                                       |

c-section—caesarean section.

Table 4. Sociodemographic and obstetric variables and health-enhancing behaviors in relation to maternal experience.

| Data        |  | No Maternal Experience<br>% (n/N) | 1 Child<br>% (n/N) | 2 Children<br>% (n/N) | ≥3 Children<br>% (n/N) | Chi <sup>2</sup> Test<br>p-Value        |
|-------------|--|-----------------------------------|--------------------|-----------------------|------------------------|---|
| Age (years) | Mean ± SD                              | 30.6 ± 3.7                        | 29.6 ± 4.1         | 32.1 ± 3.8            | 34.8 ± 4.5             | Chi <sup>2</sup> = 119.02<br>p < 0.0001 |
|             | Median (interquartile range<br>25–75%) | 30.0 (28.0–32.0)                  | 29.0 (27.0–32.0)   | 32.0 (29.0–35.0)      | 36.0 (32.0–38.0)       |   |
|             | 18–25                                  | 5.4% (5/92)                       | 15.1% (73/483)     | 4.1% (11/268)         | 3.6% (4/110)           |   |
|             | 26–34                                  | 80.4% (74/92)                     | 71.8% (347/483)    | 67.5% (181/268)       | 41.8% (46/110)         |   |
|             | ≥35                                    | 14.1% (13/92)                     | 13.3% (64/483)     | 28.0% (75/268)        | 54.5% (60/110)         |   |

Table 4. Cont.

| Data  |  | No Maternal Experience<br>% (n/N) | 1 Child<br>% (n/N) | 2 Children<br>% (n/N) | ≥3 Children<br>% (n/N) | Chi <sup>2</sup> Test<br><i>p</i> -Value      |
|---|--|-----------------------------------|--------------------|-----------------------|------------------------|---|
| Pre-pregnancy BMI, kg/m <sup>2</sup>              | Mean ± SD                              | 23.8 ± 4.3                        | 23.2 ± 4.2         | 23.6 ± 4.3            | 24.0 ± 4.8             | Chi <sup>2</sup> = 6.25<br><i>p</i> < 0.72    |
|   | Median (interquartile range<br>25–75%) | 23.0 (20.7–25.7)                  | 22.2 (20.3–25.3)   | 22.7 (20.6–25.3)      | 23.5 (20.5–27.1)       |   |
|   | Underweight (<18.5)                    | 5.4% (5/92)                       | 7.7% (37/483)      | 4.9% (13/268)         | 8.2% (9/110)           |   |
|   | Normal Weight (18.5–24.9)              | 64.1% (59/92)                     | 66.3% (320/483)    | 67.5% (181/268)       | 58.2% (64/110)         |   |
|   | Overweight (25–29.9)                   | 19.6% (18/92)                     | 17.2% (83/483)     | 17.5% (47/268)        | 23.6% (26/110)         |   |
| Residence   | Obesity (≥30)                          | 10.9% (10/92)                     | 9.1% (44/483)      | 9.7% (26/268)         | 10.0% (11/110)         | Chi <sup>2</sup> = 20.33<br><i>p</i> < 0.006  |
|   | Urban, Above 100,000 Residents         | 62.0% (57/92)                     | 50.9% (246/483)    | 44.4% (119/268)       | 34.5% (38/110)         |   |
|   | Urban, 10,000–100,000 Residents        | 15.2% (14/92)                     | 18.6% (90/483)     | 21.2% (57/268)        | 31.8% (35/110)         |   |
|   | Urban, <10,000 Residents               | 8.7% (8/92)                       | 6.6% (32/483)      | 7.1% (19/268)         | 6.4% (7/110)           |   |
| Education   | Rural                                  | 14.1% (13/92)                     | 24.0% (116/483)    | 26.9% (72/268)        | 27.3% (30/110)         | Chi <sup>2</sup> = 32.42<br><i>p</i> < 0.0001 |
|   | Vocational and Primary                 | 0% (0/92)                         | 1.9% (9/483)       | 3.0% (8/268)          | 5.5% (6/110)           |   |
|   | High School                            | 7.6% (7/92)                       | 18.2% (88/483)     | 16.4% (44/268)        | 32.7% (36/110)         |   |
| Marital status                                    | University                             | 92.4% (85/92)                     | 80.1% (387/483)    | 80.2% (215/268)       | 61.8% (68/110)         | Chi <sup>2</sup> = 18.11<br><i>p</i> < 0.008  |
|   | Married                                | 82.6% (76/92)                     | 78.1% (377/483)    | 86.6% (232/268)       | 88.2% (97/110)         |   |
|   | Cohabiting                             | 17.4% (16/92)                     | 19.0% (92/483)     | 12.7% (34/268)        | 10.0% (11/110)         |   |
| Mode of delivery                                  | Single Parent & Divorced               | 0% (0/92)                         | 3.1% (15/483)      | 0.4% (1/268)          | 1.8% (2/110)           | Chi <sup>2</sup> = 53.04<br><i>p</i> < 0.0001 |
|   | Vaginal Birth                          | 52.2% (48/92)                     | 56.1% (271/483)    | 56.3% (151/268)       | 57.3% (63/110)         |   |
|   | Elective C-Section                     | 14.1% (13/92)                     | 17.8% (86/483)     | 30.6% (82/268)        | 34.5% (38/110)         |   |
| Knowledge level regarding<br>maternal vaccination | Emergency C-Section                    | 33.7% (31/92)                     | 26.3% (127/483)    | 12.7% (34/268)        | 8.2% (9/110)           | Chi <sup>2</sup> = 3.97<br><i>p</i> < 0.68    |
|   | Poor                                   | 42.4% (39/92)                     | 43.3% (209/483)    | 43.7% (117/268)       | 51.8% (57/110)         |   |
|   | Moderate                               | 15.2% (14/92)                     | 15.7% (76/483)     | 13.1% (35/268)        | 13.6% (15/110)         |   |
| Detailed  |  | 42.4% (39/92)                     | 41.2% (199/483)    | 42.9% (115/268)       | 34.5% (38/110)         |   |



Table 4. Cont.

| Data                  |     | No Maternal Experience<br>% (n/N) | 1 Child<br>% (n/N) | 2 Children<br>% (n/N) | ≥3 Children<br>% (n/N) | Chi <sup>2</sup> Test<br><i>p</i> -Value   |
|-----------------------|-----|-----------------------------------|--------------------|-----------------------|------------------------|--|
| COVID-19 vaccination  | Yes | 72.8% (67/92)                     | 65.4% (316/483)    | 67.5% (181/268)       | 69.1% (65/110)         | Chi <sup>2</sup> = 4.75<br><i>p</i> < 0.19 |
|                       | No  | 27.2% (25/92)                     | 34.8% (168/483)    | 32.1% (86/268)        | 40.9% (45/110)         |  |
| Influenza vaccination | Yes | 21.7% (20/92)                     | 16.6% (80/483)     | 21.6% (58/268)        | 13.6% (15/110)         | Chi <sup>2</sup> = 7.00<br><i>p</i> < 0.07 |
|                       | No  | 78.3% (72/92)                     | 83.6% (404/483)    | 78.0% (209/268)       | 86.4% (95/110)         |  |
| Dual vaccination      | Yes | 19.6% (18/92)                     | 14.3% (69/483)     | 19.0% (51/268)        | 10.0% (11/110)         | Chi <sup>2</sup> = 6.86<br><i>p</i> < 0.08 |
|                       | No  | 80.4% (74/92)                     | 85.9% (415/483)    | 80.6% (216/268)       | 90.0% (99/110)         |  |

c-section—caesarean section.

### 3.5. Associations Between Sociodemographic Variables and Dual Vaccination Among Mothers

The multivariate logistic analysis showed that predictors of dual vaccination include the mother's age, BMI, place of residence, and knowledge level regarding maternal vaccination (Table 5).

**Table 5.** Predictors of maternal vaccination.

| Data   | Odds Ratio (OR) | 95% Lower—Upper Confidence Interval (CI) | p-Value |
|--|-----------------|--|---------|
| Age  | 1.07            | 1.02–1.11                                | 0.005   |
| BMI  |                 |  |         |
| Normal Weight (18.5–24.9) (ref)                |                 |  |         |
| Underweight (<18.5)                            | 0.99            | 0.49–2.02                                | 0.98    |
| Overweight (25–29.9)                           | 0.65            | 0.39–1.10                                | 0.11    |
| Obese ( $\geq 30$ )                            | 0.34            | 0.15–0.77                                | 0.009   |
| Residence                                      |                 |  |         |
| Urban, >100,000 Residents (ref)                |                 |  |         |
| Urban, 10,000–100,000 Residents                | 0.52            | 0.31–0.87                                | 0.02    |
| Urban, <10,000 Residents                       | 0.49            | 0.21–1.14                                | 0.097   |
| Rural  | 0.52            | 0.31–0.88                                | 0.01    |
| Education                                      |                 |  |         |
| University (ref)                               |                 |  |         |
| High School                                    | 0.66            | 0.36–1.21                                | 0.18    |
| Vocational and Primary                         | 1.77            | 0.56–5.73                                | 0.33    |
| Knowledge Level Regarding Maternal Vaccination |                 |  |         |
| High (ref)                                     |                 |  |         |
| Moderate                                       | 1.05            | 0.64–1.70                                | 0.86    |
| Low  | 0.31            | 0.19–0.45                                | <0.001  |
| Feeding Strategy                               |                 |  |         |
| Breastfeeding (ref)                            |                 |  |         |
| Mixed Feeding                                  | 0.878           | 0.41–1.48                                | 0.45    |
| Formula Feeding                                | 0.87            | 0.41–1.84                                | 0.72    |

Respondents with BMIs categorizing them as obese significantly ( $p < 0.009$ ) less often decided to receive dual vaccination (OR = 0.34; 95% CI = 0.15–0.77). Similarly, a lower rate of dual vaccination was observed for respondents from rural areas and medium-sized urban areas (10,00–100,000 residents) (OR = 0.52; 95% CI = 0.31–0.88,  $p = 0.01$  and OR = 0.52; 95% CI = 0.31–0.87, respectively,  $p = 0.02$ ). A low knowledge level regarding maternal vaccination was associated with not being vaccinated (OR = 0.31; 95% CI = 0.19–0.45,  $p < 0.001$ ) (Table 5).

### 3.6. Associations Between Sociodemographic Variables, Health-Enhancing Behaviors, and Neonatal Feeding Strategy

For the analyzed group of mothers, the multivariate analysis identified three potential predictors of choosing breastfeeding for neonatal feeding: BMI, maternal experience, and knowledge level regarding maternal vaccination.

The respondents with BMIs categorizing them as obese significantly ( $p < 0.001$ ) less often choose breastfeeding as a method of neonatal feeding (OR = 0.40; 95% CI = 0.24–0.65). Similarly, a low level of knowledge regarding maternal vaccination was associated with a lower rate of breastfeeding (OR = 0.63; 95% CI = 0.44–0.90,  $p < 0.02$ ). Additionally, a lack of prior experience of motherhood was associated with a lower rate of breastfeeding (OR = 0.41; 95% CI = 0.25–0.67  $p < 0.0001$ ).

Influenza and/or COVID-19 vaccination were not significantly associated with breastfeeding as a strategy for feeding (Table 6).

**Table 6.** Predictors of breastfeeding among mothers.

| Data  | Odds Ratio (OR) | 95% Lower—Upper Confidence Interval (CI) | p-Value |
|---|-----------------|--|---------|
| <b>BMI</b>  |                 |  |         |
| Normal Weight (18.5–24.9) (ref)                           |                 |  |         |
| Underweight (<18.5)                                       | 0.77            | 0.41–1.45                                | 0.42    |
| Overweight (25–29.9)                                      | 0.94            | 0.61–1.46                                | 0.80    |
| Obese ( $\geq 30$ )                                       | 0.40            | 0.24–0.65                                | <0.001  |
| <b>Maternal experience</b>                                |                 |  |         |
| 1 child (ref)   |                 |  |         |
| no maternal experience                                    | 0.41            | 0.25–0.67                                | <0.0001 |
| 2nd child   | 1.06            | 0.71–1.56                                | 0.78    |
| 3rd and more child  | 1.76            | 0.96–3.26                                | 0.07    |
| <b>Level of Knowledge Regarding Perinatal Vaccination</b> |                 |  |         |
| High (ref)  |                 |  |         |
| Moderate  | 1.15            | 0.67–1.97                                | 0.62    |
| Low   | 0.63            | 0.44–0.90                                | 0.02    |
| <b>Influenza Vaccination</b>                              |                 |  |         |
| Yes (ref)   |                 |  |         |
| No  | 0.69            | 0.23–2.08                                | 0.52    |
| <b>Dual Vaccination</b>                                   |                 |  |         |
| Yes (ref)   |                 |  |         |
| No  | 1.15            | 0.35–3.77                                | 0.82    |

#### 4. Discussion

Maternal vaccination and breastfeeding are important aspects of public health that should be highlighted by medical staff caring for pregnant and postpartum women. A working group [28] has pointed out that pregnancy is associated with increased severity of some infectious diseases. Given the incidence of influenza/COVID-19 in pregnancy and the neonatal morbidity due to infection in early postnatal life, maternal vaccination in pregnancy is recommended [28,42]. The mother and child form a unique relationship, called the mother–infant dyad, and in light of this, health-enhancing behaviors are crucial for the short- and long-term health of both. This study sheds light on mothers' levels of knowledge regarding vaccine-induced humoral immunity for mother–infant dyads and identifies variables associated with choosing breastfeeding as an infant feeding strategy.

In Poland, according to the guidelines of the Polish Society of Gynecologists and Obstetricians, influenza/COVID-19 vaccination is free of charge for pregnant women, who are considered as a priority category [23,26,27,70,71]. Despite recommendations by obstetricians and the well-established status of influenza vaccination, in the present study, less than 20% of respondents had decided on influenza vaccination; by contrast, in high-risk populations, the optimal vaccination coverage target is 95% [72]. The present data are in line with those in previous reports [73–75], which showed that influenza vaccination coverage remains low, especially in low- and middle-income countries [76]. A working group [73] has found that in many developed countries, the influenza vaccination rates are low due to concerns about vaccine safety, as well as due to individuals downplaying the disease and underestimating the advantage of vaccination. In contrast, COVID-19 vaccination was reported by 66.0% of respondents (66.5% in the breastfeeding group, 67.0% in the mixed-feeding group, and 60.5% in the formula-feeding group). Dual vaccination was recorded for only 15.6% of respondents (16.6% in the breastfeeding group, 12.6% in the mixed-feeding group, and 10.5% in the formula-feeding group). The stark differences in vaccination acceptance may be the result of a low level of knowledge among mothers about the advantages of perinatal vaccination, insufficient promotion of influenza vaccination by

public institutions in the country, and inadequate education of women of reproductive age. Currently, vaccinations are the most common method used to prevent infectious diseases. Therefore, public-health programs should be adapted to the needs of each population by identifying key factors influencing the avoidance of vaccination by pregnant women and mothers. This study showed that lessons learned from the COVID-19 pandemic do not impact maternal decisions regarding perinatal vaccination. Although COVID-19 vaccination was reported by 66% of respondents, the rates of influenza vaccination were low among the analyzed groups. Therefore, the successful promotion of maternal vaccinations should be focused on providing reliable information to women of reproductive age in areas with negative outcomes of disease and the possibility of avoiding them by vaccination.

In this study, we identified age, BMI, place of residence, and knowledge level regarding maternal vaccination as factors significantly associated with willingness to be vaccinated. The significant differences between those aged 18–25 vs. 26–34 and those aged 18–25 vs.  $\geq 35$  and between those residing in urban areas with  $>10,000$  residents and those residing in rural areas (Table 3) suggest that young women living outside urban areas should be a target of campaigns promoting maternal vaccinations. Our data align with those of previous reports [77,78] demonstrating that age, rural residency, and chronic diseases were associated with avoiding influenza/COVID-19 vaccination. Data demonstrating the impact of obesity/BMI of respondents on the likelihood of accepting COVID-19 vaccination are limited. According to Kessy et al. [79], the likelihood of accepting COVID-19 vaccination was significantly associated with respondents' age, BMI, education, and residency, and these data are in line with our results. The authors pointed out that high BMI and comorbidities may influence an individual's inclination to accept vaccination [79]. Townsend et al. [80] noted that vaccine hesitancy specifically among obese individuals is concerning for several reasons, including prevalent weight bias, which hinders their engagement in the healthcare system, marginalizes people with obesity, and reduces use of recommended preventive care. Additionally, high BMI is associated with lower COVID-19 vaccine effectiveness and a reduced immune response to vaccination [81,82]. The authors identified, as the main reasons, the poorer innate and adaptive immune responses, as well as the associated impaired T-cell response, associated with obesity and suggested the need for a booster to enhance protection [82].

It is crucial for dedicated programs to highlight that mothers, by accepting vaccines during the perinatal period, may contribute to the well-being of their infants. As the experience of the COVID-19 pandemic showed, a relatively high COVID-19 vaccination rate (66%) can be achieved, whereas double vaccination was reported by only 15.6% of respondents in the study group. These rates are dramatically low and require urgent corrective actions. As reported previously [67,75], the most common reason for avoiding COVID-19 and influenza vaccination was possible overall post-vaccination complications.

Moreover, in this study, we observed that breastfeeding mothers, in comparison to formula- and mixed-feeding women, were more likely to have lower pre-pregnancy BMI and maternal experience; this finding is in line with data presented by other authors [83]. It has been reported that mothers with higher BMI are less likely to develop successful breastfeeding in comparison to normal-weight women [83,84]. The main reasons for the lower rate of breastfeeding in the obstetrical population with overweight or obesity are delayed lactogenesis, failure to initiate breastfeeding, and/or exclusive breastfeeding only during hospital admission [83,84].

The impact of prior experience of motherhood on rates of breastfeeding was probably the net result of previous positive experience with breastfeeding practices, and this supposition is consistent with previous reports [85,86]. A working group [87] has reported that a mother's education level plays a pivotal role in the choice of infant feeding strategy.

Although we did not observe a significant association between education level and mothers' decisions regarding neonatal feeding (Table 3), we noted that this variable was significantly related to prior experience of motherhood (Table 4). Wako et al. [88] reported that maternal education has an impact on socioeconomic status, which can be associated with health-enhancing behavior and also improve understanding of the short- and long-term health benefits of breastfeeding for the mother–infant dyad. Our results are convergent with these findings, and we suggest that women with higher education and maternal experience might have higher motivation to acquire knowledge in areas relevant to improving maternal and infant health. Moreover, the level of knowledge regarding maternal vaccination was significantly different between breastfeeding mothers and women who decided on formula or mixed feeding, and these observed data are in line with the findings of other authors [89]. They [89] found that mothers' knowledge regarding infants' nutrition is not sufficient and that complementary feeding practices require corrective action. In contrast to the results of previous research [90,91], in this study, we did not observe significant differences in maternal age between the analyzed groups. Additionally, no significant difference in vaccination status was found between breastfeeding mothers and women who used formula or mixed feeding.

The protective effect of maternal vaccination as a strategy to reduce susceptibility to infection in newborns and infants is well established [37,92–94]. As shown in this study, the promotion of COVID-19 vaccination among the Polish population of women of reproductive age translates into a high rate of vaccination among respondents. At the same time, in the years 2021–2022, influenza vaccination was less strongly promoted and the rate of vaccination in the same population was significantly lower. Our data indicated that campaigns promoting the safety of vaccinations and the broad range of benefits for the mother and infants are needed. The linking of the positive short- and long-term advantages of maternal vaccination might translate to a higher rate of annual vaccination. Previous studies [37,95,96] have reported that providing reliable information about the benefits of immunization effectively promotes maternal vaccination. In our study, we found that perinatal vaccination in mothers was not associated with breastfeeding as a strategy for infant feeding. Therefore, independent of the promotional campaigns regarding maternal vaccination, women of reproductive age should be informed about the valuable effect of maternal milk and the advantages of breastfeeding for both infants and mothers. The data indicate that the willingness of lactating women to get the COVID-19 vaccine was high, and factors associated with receiving vaccination in the obstetric population include medical history, belief that the COVID-19 vaccine is safe during breastfeeding, and the country of residence [97,98]. On the other hand, our study and the results of another group [99] are consistent and show that willingness to get the influenza vaccine in the obstetric population is low. There is a great need for urgent implementation of corrective actions to enhance vaccination efforts. Our study showed that in the Polish obstetric population, special education programs should be focused especially on young, primiparous women with overweight and obesity (Tables 3, 5 and S2). We believe that reliable information regarding maternal vaccination and health enhancing-behaviors, including breastfeeding practices, improve general health literacy.

#### *Strength and Limitations*

The undeniable strength of the present study is that it fills the knowledge gap regarding maternal vaccination among women of reproductive age. Another strength is the identification of sociodemographic predictors of avoiding dual vaccination. Based on these, general health-promoting programs aimed at pregnant women and mothers may be created. Additionally, our results offer a valuable and useful perspective on which factors

are pivotal for shaping health-enhancing behaviors. This may translate into the well-being, in first months of postnatal life, of future generations.

We should acknowledge some limitations of our studies. First, attitudes regarding maternal vaccination among women might have changed during the data collection period. Future studies should explore the temporal dynamics of willingness to receive maternal vaccinations among women of reproductive age. Second, the study included 953 mothers who were recruited for the study through local parenting groups such as Facebook. Hence, the percentage of breastfeeding reported here does not represent the rate of neonatal breastfeeding in the general Polish population. In this study, we focused on the impact of some sociodemographic factors, while we did not consider individual-level psychological variables, which also play an important role in attitudes to vaccination. Moreover, continuation of research in this area might fill the knowledge gap concerning dual vaccination among women of reproductive age, and investigating the interplay between individual, sociodemographic, and sociocultural (e.g., social norms, peer influence, community support) variables might enable an in-depth and multi-faceted analysis of the problem of vaccination among pregnant and breastfeeding mothers. This research was exploratory, and some covariables were not accounted for. These included the rates of pertussis vaccination, maternal socio-economic status, obstetric interventions, and reasons for avoiding vaccination. All these factors have been shown to influence breastfeeding practices [76,100–103].

## 5. Conclusions

In the population of Polish mothers, primiparous women of reproductive age should be given special care, which includes knowledge regarding maternal vaccination. Older maternal age, lower BMI, living in urban areas with >100,000 residents, and a high level of knowledge regarding prenatal vaccination were identified as the main factors associated with increasing mothers' willingness to be vaccinated. In the future, a pivotal strategy will be to generate specific antibodies in pregnant women that will have protective benefits for the infant. Currently, research is being conducted to develop new vaccines for immunizing mothers, namely vaccines against cytomegalovirus (currently in phase II research) and group B streptococcus to prevent late infections in newborns (phase II research) [28,104,105]. As demonstrated in this study, the influenza vaccination and/or COVID-19 vaccination was not associated with breastfeeding as a neonatal feeding strategy. In light of this, independent of the mother's vaccination status, women should be informed about the unique advantages of breastfeeding such as preventing infections, modulating gut microbiota, and supporting mucosal immunity in neonates and infants. The multipronged approach of prenatal education and support should make women aware of the difficulties that can be faced by women after giving birth, especially by those who are overweight or obese (i.e., delayed lactogenesis, latching issues). Proper education during pregnancy, support from medical-care staff including healthcare workers and midwives, assistance from lactation consultants, and regular follow-up appointments to monitor the neonate's growth and the mother's breastfeeding experience can help identify and address issues early, ultimately improving outcomes for the mother–infant dyad.

**Supplementary Materials:** The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/vaccines13040376/s1>, Table S1: Results of Post Hoc Test of Multiple Comparisons with Bonferroni correction for significant outcomes: sociodemographic and health-enhancing behaviors of respondents in relation to maternal vaccination status; Table S2: Results of Post Hoc Test of Multiple Comparisons with Bonferroni correction for significant outcomes: sociodemographic and obstetric variables and health-enhancing behaviors in relation to neonatal feeding strategy; Table S3: Results of Post Hoc Test of Multiple Comparisons with Bonferroni correction for significant



outcomes: Sociodemographic and obstetric variables and health-enhancing behaviors in relation to maternal experience.

**Author Contributions:** Conceptualization, J.L.-K. and M.O.-P.; methodology, J.L.-K. and M.O.-P.; data curation, J.L.-K. and M.O.-P.; investigation, J.L.-K. and M.O.-P.; writing—original draft preparation, J.L.-K.; writing—review and editing, J.L.-K. and M.O.-P.; supervision, M.O.-P.; funding acquisition, J.L.-K. and M.O.-P. All authors have read and agreed to the published version of the manuscript.

**Funding:** The authors acknowledge funding support from Wroclaw Medical University, Poland.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee at Wroclaw Medical University (No KB-356/2021; date of approval: 26 April 2021).

**Informed Consent Statement:** The survey was anonymous and participation in it was voluntary. Completing the questionnaire meant unequivocal consent to participate in the study.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy restrictions.

**Conflicts of Interest:** The authors declare no conflicts of interest.

## References

1. Ellwanger, J.H.; Veiga, A.B.G.; Kaminski, V.L.; Valverde-Villegas, J.M.; Freitas, A.W.Q.; Chies, J.A.B. Control and prevention of infectious diseases from a One Health perspective. *Genet. Mol. Biol.* **2021**, *44*, e20200256. [\[CrossRef\]](#) [\[PubMed\]](#)
2. van den Berg, J.P.; Westerbeek, E.A.; van der Klis, F.R.; Berbers, G.A.; van Elburg, R.M. Transplacental transport of IgG antibodies to preterm infants: A review of the literature. *Early Hum. Dev.* **2011**, *87*, 67–72. [\[CrossRef\]](#)
3. Lozano, N.A.; Lozano, A.; Marini, V.; Saranz, R.J.; Blumberg, R.S.; Baker, K.; Agresta, M.F.; Ponzio, M.F. Expression of FcRn receptor in placental tissue and its relationship with IgG levels in term and preterm newborns. *Am. J. Reprod. Immunol.* **2018**, *80*, e12972. [\[CrossRef\]](#)
4. Coler, C.; King-Nakaoka, E.; Every, E.; Chima, S.; Vong, A.; Del Rosario, B.; VanAbel, R.; Adams Waldorf, K.M. Impact of Infections During Pregnancy on Transplacental Antibody Transfer. *Vaccines* **2024**, *12*, 1199. [\[CrossRef\]](#) [\[PubMed\]](#)
5. Gusdon, J.P. Fetal and maternal immunoglobulin levels during pregnancy. *Am. J. Obstet. Gynecol.* **1969**, *103*, 895–900. [\[CrossRef\]](#) [\[PubMed\]](#)
6. Ohlsson, A.; Lacy, J.B. Intravenous immunoglobulin for suspected or proven infection in neonates. *Cochrane Database Syst. Rev.* **2020**, *1*, CD001239. [\[CrossRef\]](#)
7. Justiz Vaillant, A.A.; Hoyte, T.; Davis, N.; Deonarinesingh, C.; De Silva, A.; Dhanpaul, D.; Dookhoo, C.; Doorpat, J.; Dopson, A.; Durgapersad, J.; et al. A Systematic Review of the Clinical Diagnosis of Transient Hypogammaglobulinemia of Infancy. *Children* **2023**, *10*, 1358. [\[CrossRef\]](#)
8. Maródi, L. Neonatal innate immunity to infectious agents. *Infect. Immun.* **2006**, *74*, 1999–2006. [\[CrossRef\]](#)
9. Basha, S.; Surendran, N.; Pichichero, M. Immune responses in neonates. *Expert Rev. Clin. Immunol.* **2014**, *10*, 1171–1184.
10. Demers-Mathieu, V.; Underwood, M.A.; Beverly, R.L.; Nielsen, S.D.; Dallas, D.C. Comparison of Human Milk Immunoglobulin Survival during Gastric Digestion between Preterm and Term Infants. *Nutrients* **2018**, *10*, 631. [\[CrossRef\]](#)
11. Atyeo, C.; Alter, G. The multifaceted roles of breast milk antibodies. *Cell* **2021**, *184*, 1486–1499. [\[CrossRef\]](#) [\[PubMed\]](#)
12. Semmes, E.C.; Chen, J.L.; Goswami, R.; Burt, T.D.; Permar, S.R.; Fouda, G.G. Understanding Early-Life Adaptive Immunity to Guide Interventions for Pediatric Health. *Front. Immunol.* **2021**, *11*, 595297.
13. Stafford, L.; Valcarce, V.; Henry, M.; Neu, J.; Parker, L.; Martina, M.; Vicuna, V.; Gowen, T.; Cato, E.; Kosik, I.; et al. Detection of SARS-CoV-2 IgA and IgG in human milk and breastfeeding infant stool 6 months after maternal COVID-19 vaccination. *J. Perinatol.* **2023**, *43*, 775–781. [\[CrossRef\]](#) [\[PubMed\]](#)
14. Pérez-Cano, F.J.; Demers-Mathieu, V.; Billeaud, C. Editorial: Human milk, nutrition and infant development. *Front. Nutr.* **2024**, *11*, 1525112.
15. Branche, A.R.; Falsey, A.R. Parainfluenza Virus Infection. *Semin. Respir. Crit. Care Med.* **2016**, *37*, 538–554.
16. Wildenbeest, J.G.; van der Schee, M.P.; Hashimoto, S.; Benschop, K.S.; Minnaar, R.P.; Sprikkelman, A.B.; Haarman, E.G.; van Aalderen, W.M.; Sterk, P.J.; Pajkrt, D.; et al. Prevalence of rhinoviruses in young children of an unselected birth cohort from the Netherlands. *Clin. Microbiol. Infect.* **2016**, *22*, 736.e9–736.e15.

17. Ljubin-Sternak, S.; Meštrović, T.; Ivković-Jureković, I.; Kolarić, B.; Slović, A.; Forčić, D.; Tot, T.; Mijač, M.; Vraneš, J. The Emerging Role of Rhinoviruses in Lower Respiratory Tract Infections in Children—Clinical and Molecular Epidemiological Study From Croatia, 2017–2019. *Front. Microbiol.* **2019**, *10*, 2737.
18. Chaiut, W.; Sapbamrer, R.; Dacha, S.; Sudjaritruk, T.; Malasao, R. Epidemiology and associated factors for hospitalization related respiratory syncytial virus infection among children less than 5 years of age in Northern Thailand. *J. Infect. Public Health* **2023**, *16*, 1659–1665.
19. Munro, A.P.S.; Martínón-Torres, F.; Drysdale, S.B.; Faust, S.N. The disease burden of respiratory syncytial virus in Infants. *Curr. Opin. Infect. Dis.* **2023**, *36*, 379–384. [\[CrossRef\]](#)
20. Li, Y.; Wu, Z.; Yan, Y.; Shi, Y.; Huang, J.; Du, H.; Du, Q.; Li, Y.; Lin, Y.; Liu, D.; et al. Prevalence of respiratory viruses among hospitalized children with lower respiratory tract infections during the COVID-19 pandemic in Wuhan, China. *Int. J. Infect. Dis.* **2024**, *139*, 6–12.
21. Argun, M.; İnan, D.B.; Hörmet ÖZ, H.T.; Duyar, M.O.; Başargan, G.; Elmalı, F.; Çelik, İ. Lymphocyte Subsets in Mild COVID-19 Pediatric Patients. *Turk. Arch. Pediatr.* **2022**, *57*, 210–215. [\[CrossRef\]](#) [\[PubMed\]](#)
22. Luo, C.; Chen, W.; Cai, J.; He, Y. The mechanisms of milder clinical symptoms of COVID-19 in children compared to adults. *Ital. J. Pediatr.* **2024**, *50*, 28. [\[CrossRef\]](#)
23. Polish Society of Gynecologists and Obstetricians Position on Vaccination of Pregnant Women Against COVID-19. Available online: <https://www.ptgin.pl/artykul/stanowisko-ptgip-dotyczace-szczepien-kobiet-ciezarnych-przeciwko-covid19> (accessed on 15 January 2025). (In Polish).
24. Antczak, A.; Kucha, E.; Nitsch-Osuch, A.; Sieroszewski, P.; Wielgoś, M.; Zimmer, M. Stanowisko Ekspertów OPZG i PTGiP Dotyczące Szczepienia Przeciw Grypie Kobiet w Ciąży. 2020. Available online: <https://www.ptgin.pl/sites/scm/files/2022-01/09.2020%20Stanowisko%20ekspert%C3%B3w%20OPZG%20i%20PTGiP%20dotycz%C4%85ce%20szczepienia%20przeciw%20grypie%20kobiet%20w%20ci%C4%85%C5%BCy.pdf> (accessed on 15 January 2025). (In Polish).
25. Szela, J.; Mastalerz-Migas, A. Lekarze rodzinni w Polsce wobec szczepienia kobiet w ciąży—Postawy i praktyka. 2019. Available online: <https://www.mp.pl/szczepienia/artykuly> (accessed on 15 January 2025). (In Polish).
26. Seremak-Mrozikiewicz, A.; Nitsch-Osuch, A.; Czajkowski, K.; Drews, K.; Huras, H.; Kalinka, J.; Kuchar, E.; Leszczynska-Gorzela, B.; Mastalerz-Migas, A.; Swiatkowska-Freund, M.; et al. Guidelines of the Polish Society of Gynecologists and Obstetricians, the Polish Society for Vaccinology, and the Polish Society for Family Medicine on vaccinating women with reproductive plans and pregnant or breastfeeding women. *Ginek. Pol.* **2023**, *94*, 670–682. [\[CrossRef\]](#) [\[PubMed\]](#)
27. Jurga, J.; Mierzwa, G.; Kuciel, J.A.; Kołak, M.; Jaworowski, A.; Huras, H. Maternal Vaccination in Pregnancy: An Assessment of Influenza, Pertussis, and COVID-19 Vaccination Rates in Cracow, Poland. *Med. Sci. Monit.* **2024**, *30*, e943304. [\[CrossRef\]](#) [\[PubMed\]](#)
28. Nassar, A.H.; Hobeika, E.; Chamsy, D.; El-Kak, F.; Usta, I.M. Vaccination in pregnancy. *Int. J. Gynaecol. Obstet.* **2023**, *162*, 18–23. [\[CrossRef\]](#)
29. Ciapponi, A.; Berrueta, M.; P K Parker, E.; Bardach, A.; Mazzoni, A.; Anderson, S.A.; Argento, F.J.; Ballivian, J.; Bok, K.; Comandé, D.; et al. Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis. *Vaccine* **2023**, *41*, 3688–3700. [\[CrossRef\]](#)
30. Favilli, A.; Mattei Gentili, M.; De Paola, F.; Laganà, A.S.; Vitagliano, A.; Bosco, M.; Cicinelli, E.; Chiantera, V.; Uccella, S.; Parazzini, F.; et al. COVID-19 and Pregnancy: An Updated Review about Evidence-Based Therapeutic Strategies. *J. Pers. Med.* **2023**, *13*, 1035. [\[CrossRef\]](#)
31. Norman, M.; Magnus, M.C.; Söderling, J.; Juliusson, P.B.; Navér, L.; Örtqvist, A.K.; Håberg, S.; Stephansson, O. Neonatal Outcomes After COVID-19 Vaccination in Pregnancy. *JAMA.* **2024**, *331*, 396–407. [\[CrossRef\]](#)
32. Munoz, F.M.; Jamieson, D.J. Maternal Immunization. *Obstet. Gynecol.* **2019**, *133*, 739–753. [\[CrossRef\]](#)
33. Röbl-Mathieu, M.; Kunstein, A.; Liese, J.; Mertens, T.; Wojcinski, M. Vaccination in Pregnancy. *Dtsch. Arztebl. Int.* **2021**, *118*, 262–268. [\[CrossRef\]](#)
34. Demers-Mathieu, V.; DaPra, C.; Medo, E. Influenza Vaccine Associated with the Gene Expression of T Cell Surface Markers in Human Milk. *Breastfeed. Med.* **2022**, *17*, 218–225. [\[PubMed\]](#)
35. Demers-Mathieu, V. Editorial: Breast milk and passive immunity during the COVID-19 pandemic. *Front. Nutr.* **2023**, *10*, 1155901.
36. Suteerotrakool, O.; Mekangkul, E.; Ananta, P.; Maitreechit, D.; Khabuan, S.; Sodsai, P.; Hirankarn, N.; Thumborn, R.; Chomtho, S. The Persistence of Specific Immunoglobulin A Against SARS-CoV-2 in Human Milk After Maternal COVID-19 Vaccination. *Breastfeed. Med.* **2023**, *18*, 943–950.
37. Quincer, E.M.; Cranmer, L.M.; Kamidani, S. Prenatal Maternal Immunization for Infant Protection: A Review of the Vaccines Recommended, Infant Immunity and Future Research Directions. *Pathogens* **2024**, *13*, 200. [\[CrossRef\]](#) [\[PubMed\]](#)
38. Maltezou, H.C.; Rodolakis, A. Vaccination of pregnant women against influenza: What is the optimal timing? *Hum. Vaccin. Immunother.* **2021**, *17*, 2723–2727.

39. Zaman, K.; Roy, E.; Arifeen, S.E.; Rahman, M.; Raqib, R.; Wilson, E.; Omer, S.B.; Shahid, N.S.; Breiman, R.F.; Steinhoff, M.C. Effectiveness of maternal influenza immunization in mothers and infants. *N. Engl. J. Med.* **2008**, *359*, 1555–1564.
40. Lopez, P.A.; Nziza, N.; Chen, T.; Shook, L.L.; Burns, M.D.; Demidkin, S.; Jasset, O.; Akinwunmi, B.; Yonker, L.M.; Gray, K.J.; et al. Placental transfer dynamics and durability of maternal COVID-19 vaccine-induced antibodies in infants. *iScience* **2024**, *27*, 109273.
41. Tannis, A.; Englund, J.A.; Perez, A.; Harker, E.J.; Staat, M.A.; Schlaudecker, E.P.; Halasa, N.B.; Stewart, L.S.; Williams, J.V.; Michaels, M.G.; et al. SARS-CoV-2 Epidemiology and COVID-19 mRNA Vaccine Effectiveness Among Infants and Children Aged 6 Months–4 Years—New Vaccine Surveillance Network, United States, July 2022–September 2023. *MMWR Morb. Mortal Wkly Rep.* **2023**, *72*, 1300–1306.
42. Jorgensen, S.C.J.; Drover, S.S.M.; Fell, D.B.; Austin, P.C.; D’Souza, R.; Guttmann, A.; Buchan, S.A.; Wilson, S.E.; Nasreen, S.; Schwartz, K.L.; et al. Newborn and Early Infant Outcomes Following Maternal COVID-19 Vaccination During Pregnancy. *JAMA Pediatr.* **2023**, *177*, 1314–1323.
43. Atyeo, C.; DeRiso, E.A.; Davis, C.; Bordt, E.A.; De Guzman, R.M.; Shook, L.L.; Yonker, L.M.; Fasano, A.; Akinwunmi, B.; Lauffenburger, D.A.; et al. COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in pregnant, lactating, and nonpregnant women. *Sci. Transl. Med.* **2021**, *13*, eabi8631.
44. Collier, A.-R.Y.; McMahan, K.; Yu, J.; Tostanoski, L.H.; Aguayo, R.; Ansel, J.; Chandrashekar, A.; Patel, S.; Apraku Bondzie, E.; Sellers, D.; et al. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. *JAMA* **2021**, *325*, 2370–2380.
45. Proto, A.; Agliardi, S.; Pani, A.; Renica, S.; Gazzaniga, G.; Giossi, R.; Senatore, M.; Di Ruscio, F.; Campisi, D.; Vismara, C.; et al. COVID-Vaccines in Pregnancy: Maternal and Neonatal Response over the First 9 Months after Delivery. *Biomolecules* **2024**, *14*, 435. [\[CrossRef\]](#)
46. Lauritsen, C.J.; Trinh, I.V.; Desai, S.P.; Clancey, E.; Murrell, A.E.; Rambaran, S.; Chandra, S.; Elliott, D.H.; Smira, A.R.; Mo, Z.; et al. Passive antibody transfer from pregnant women to their fetus are maximized after SARS-CoV-2 vaccination irrespective of prior infection. *J. Allergy Clin. Immunol. Glob.* **2023**, *3*, 100189.
47. Schlaudecker, E.P.; Steinhoff, M.C.; Omer, S.B.; McNeal, M.M.; Roy, E.; Arifeen, S.E.; Dodd, C.N.; Raqib, R.; Breiman, R.F.; Zaman, K. IgA and neutralizing antibodies to influenza a virus in human milk: A randomized trial of antenatal influenza immunization. *PLoS ONE* **2013**, *8*, e70867.
48. Faucette, A.N.; Pawlitz, M.D.; Pei, B.; Yao, F.; Chen, K. Immunization of pregnant women: Future of early infant protection. *Hum. Vaccin. Immunother.* **2015**, *11*, 2549–2555. [\[PubMed\]](#)
49. Suragh, T.A.; Hibbs, B.; Marquez, P.; McNeil, M.M. Age inappropriate influenza vaccination in infants less than 6 months old, 2010–2018. *Vaccine* **2020**, *38*, 3747–3751.
50. Fayad, D.; Frenck, R.W., Jr. COVID-19 Vaccines in Children. *J. Clin. Med.* **2023**, *13*, 87. [\[CrossRef\]](#) [\[PubMed\]](#)
51. Graham, R.J.; Enriquez, L.F.; Elmi, A.F.; Zavadoski, J.V.; Bielak, L.G.; Baker, C.D.; Mansbach, J.M. Influenza and COVID-19 Vaccination Rates Among Children Receiving Long-Term Ventilation. *JAMA Netw. Open.* **2024**, *7*, e2430989.
52. Artzi-Medvedik, R.; Haile, Z.T.; Chertok, I.R.A. Association Between Influenza Vaccination During Pregnancy and Breastfeeding Duration. *Breastfeed. Med.* **2022**, *17*, 484–492.
53. Weston, K.; Bullock, L.; Hsu, A.L.; Wan, X.H.; Burnam-Cole, M.; Everett, K.D.; McElroy, J.A. Maternal COVID vaccination and breastfeeding during a pandemic: Habitus and health behavior decision making. *Public Health Nurs.* **2023**, *40*, 750–757.
54. Ladomenou, F.; Moschandreas, J.; Kafatos, A.; Tselentis, Y.; Galanakis, E. Protective effect of exclusive breastfeeding against infections during infancy: A prospective study. *Arch. Dis. Child.* **2010**, *95*, 1004–1008. [\[PubMed\]](#)
55. World Health Organization (WHO). Breastfeeding. Available online: [https://www.who.int/health-topics/breastfeeding#tab=tab\\_1](https://www.who.int/health-topics/breastfeeding#tab=tab_1) (accessed on 4 March 2025).
56. Mulatu, T.; Yimer, N.B.; Alemnew, B.; Linger, M.; Liben, M.L. Exclusive breastfeeding lowers the odds of childhood diarrhea and other medical conditions: Evidence from the 2016 Ethiopian demographic and health survey. *Ital. J. Pediatr.* **2021**, *47*, 166.
57. WHO Exclusive Breastfeeding for Six Months Best for Babies Everywhere. Available online: <https://www.who.int/news/item/15-01-2011-exclusive-breastfeeding-for-six-months-best-for-babies-everywhere> (accessed on 17 January 2025).
58. Królak-Olejnik, B.; Błasiak, I.; Szczygieł, A. Promotion of breastfeeding in Poland: The current situation. *J. Int. Med. Res.* **2017**, *45*, 1976–1984.
59. Gajewska, D.; Gudej, S. The dietary habits and nutritional status of women and the length of exclusive breastfeeding. Assessment of women’s awareness of the importance of breastfeeding. *Med. Stand. Pediatr.* **2018**, *15*, 869–877.
60. Grzyb, J.; Grzyb, Ł.; Wilińska, M. Perception and practice of breastfeeding in public in Poland. *J. Mother Child* **2021**, *25*, 277–284. [\[PubMed\]](#)
61. Karcz, K.; Lehman, I.; Królak-Olejnik, B. The link between knowledge of the maternal diet and breastfeeding practices in mothers and health workers in Poland. *Int. Breastfeed. J.* **2021**, *16*, 58.
62. Kolmaga, A.; Dems-Rudnicka, K.; Garus-Pakowska, A. Attitudes and Barriers of Polish Women towards Breastfeeding—Descriptive Cross-Sectional On-Line Survey. *Healthcare* **2024**, *12*, 1744. [\[CrossRef\]](#)

63. Lis-Kuberka, J.; Orczyk-Pawiliowicz, M. Polish Women Have Moderate Knowledge of Gestational Diabetes Mellitus and Breastfeeding Benefits. *Int. J. Environ. Res. Public Health* **2021**, *18*, 10409.
64. Nancy, S.; Sindhuri, R.; Arunagirinathan, A.; Dongre, A.R. Breastfeeding Positioning and Attachment among Postnatal Mothers: A Mixed Methods Study in a Tertiary Care Hospital in Puducherry, South India. *Indian J. Community Med.* **2022**, *47*, 120–124.
65. Sultana, M.; Dhar, S.; Hasan, T.; Shill, L.C.; Purba, N.H.; Chowdhury, A.I.; Shuvo, S.D. Knowledge, attitudes, and predictors of exclusive breastfeeding practice among lactating mothers in Noakhali, Bangladesh. *Heliyon* **2022**, *8*, e11069.
66. Afreen, M.S.; Majumder, B.; Mazumder, M.; Arju, F.; Islam, S.; Majumder, B.K. Maternal Knowledge and Practice during Postnatal Period Regarding Newborn Care at Hospital Setting. *Mymensingh Med. J.* **2025**, *34*, 213–219. [[PubMed](#)]
67. Lis-Kuberka, J.; Berghausen-Mazur, M.; Orczyk-Pawiliowicz, M. Attitude and Level of COVID-19 Vaccination among Women in Reproductive Age during the Fourth Pandemic Wave: A Cross-Sectional Study in Poland. *Int. J. Environ. Res. Public Health* **2022**, *19*, 6872. [[CrossRef](#)]
68. World Health Organization (WHO). Body Mass Index. Available online: <https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/body-mass-index> (accessed on 4 March 2025).
69. Ramli, N.; Rahman, N.A.A.; Haque, M. Knowledge, attitude, and practice regarding osteoporosis among allied health sciences students in a public University in Malaysia. *Erciyes Med. J.* **2018**, *40*, 210–217. [[CrossRef](#)]
70. The Position of the Ministry of Health and the National Health Fund Regarding Vaccination of Women During Pregnancy. Available online: <https://pacjent.gov.pl/aktualnosc/czy-w-czasie-ciazy-mozna-sie-szczepic> (accessed on 15 January 2025). (In Polish)
71. World Health Organization (WHO). Updates on Monitoring Safety During Pregnancy and Breastfeeding Projects: PERLA and COVID-19 Pregnancy Cohort Study. Available online: <https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/pregnancy-and-lactation/vaccines> (accessed on 15 January 2025).
72. Fallucca, A.; Immordino, P.; Ferro, P.; Mazzeo, L.; Petta, S.; Maiorana, A.; Maranto, M.; Casuccio, A.; Restivo, V. Attitude to Co-Administration of Influenza and COVID-19 Vaccines among Pregnant Women Exploring the Health Action Process Approach Model. *Vaccines* **2024**, *12*, 470. [[CrossRef](#)]
73. Brydak, L.B.; Nitsch-Osuch, A. Vaccination against influenza in pregnant women. *Acta Biochim. Pol.* **2014**, *61*, 589–591. [[CrossRef](#)] [[PubMed](#)]
74. Samel-Kowalik, P.; Jankowski, M.; Lisiecka-Bielanowicz, M.; Ostrowska, A.; Gujski, M.; Kobuszewski, B.; Pinkas, J.; Raciborski, F. Factors Associated with Attitudes towards Seasonal Influenza Vaccination in Poland: A Nationwide Cross-Sectional Survey in 2020. *Vaccines* **2021**, *9*, 1336. [[CrossRef](#)]
75. Pisula, A.; Sienicka, A.; Pawlik, K.K.; Dobrowolska-Redo, A.; Kacperczyk-Bartnik, J.; Romejko-Wolniewicz, E. Pregnant Women's Knowledge of and Attitudes towards Influenza Vaccination during the COVID-19 Pandemic in Poland. *Int. J. Environ. Res. Public Health* **2022**, *19*, 4504. [[CrossRef](#)]
76. Gu, X.; Agrawal, U.; Midgley, W.; Bedston, S.; Anand, S.N.; Goudie, R.; Byford, R.; Joy, M.; Jamie, G.; Hoang, U.; et al. COVID-19 and influenza vaccine uptake among pregnant women in national cohorts of England and Wales. *NPJ Vaccines* **2024**, *9*, 147. [[CrossRef](#)]
77. Steinmetz, L. Sociodemographic predictors of and main reasons for COVID-19 vaccine hesitancy in eastern Oslo: A cross-sectional study. *BMC Public Health* **2022**, *22*, 1878. [[CrossRef](#)]
78. Shen, Y.; Wang, J.; Zhao, Q.; Lv, M.; Wu, J.; Nicholas, S.; Maitland, E.; He, P.; Zhu, D. Predicting future vaccination habits: The link between influenza vaccination patterns and future vaccination decisions among old aged adults in China. *J. Infect. Public Health* **2024**, *17*, 1079–1085. [[CrossRef](#)]
79. Kessy, S.J.; Wei, T.; Zhou, Y.; Zhang, W.X.; Alwy Al-Beity, F.M.; Zhang, S.S.; Du, J.; Cui, F.; Lu, Q.B. Vaccination willingness, vaccine hesitancy, and estimated coverage of SARS-CoV-2 vaccine among healthcare workers in Tanzania: A call for action. *Immun. Inflamm. Dis.* **2023**, *11*, e1126. [[PubMed](#)]
80. Townsend, M.J.; Kyle, T.K.; Stanford, F.C. COVID-19 Vaccination and Obesity: Optimism and Challenges. *Obesity (Silver Spring)* **2021**, *29*, 634–635. [[CrossRef](#)] [[PubMed](#)]
81. Wilder-Smith, A.; Frahsa, A. Impact of BMI on COVID-19 vaccine effectiveness. *Lancet Diabetes Endocrinol.* **2022**, *10*, 551–552. [[CrossRef](#)]
82. Piernas, C.; Patone, M.; Astbury, N.M.; Gao, M.; Sheikh, A.; Khunti, K.; Shankar-Hari, M.; Dixon, S.; Coupland, C.; Aveyard, P.; et al. Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: A population-based cohort study. *Lancet Diabetes Endocrinol.* **2022**, *10*, 571–580. [[PubMed](#)]
83. Ballesta-Castillejos, A.; Gómez-Salgado, J.; Rodríguez-Almagro, J.; Ortiz-Esquinas, I.; Hernández-Martínez, A. Factors that influence mothers' prenatal decision to breastfeed in Spain. *Int. Breastfeed. J.* **2020**, *15*, 97.
84. Wojcicki, J.M. Maternal prepregnancy body mass index and initiation and duration of breastfeeding: A review of the literature. *J. Womens Health* **2011**, *20*, 341–347.



85. Mohamed, M.J.; Ochola, S.; Owino, V.O. Comparison of knowledge, attitudes and practices on exclusive breastfeeding between primiparous and multiparous mothers attending Wajir District hospital, Wajir County, Kenya: A cross-sectional analytical study. *Int. Breastfeed. J.* **2018**, *13*, 11.
86. Flacking, R.; Tandberg, B.S.; Niela-Vilén, H.; Jónsdóttir, R.B.; Jonas, W.; Ewald, U.; Thomson, G. Positive breastfeeding experiences and facilitators in mothers of preterm and low birthweight infants: A meta-ethnographic review. *Int. Breastfeed. J.* **2021**, *16*, 88. [\[CrossRef\]](#)
87. Wesołowska, A.; Walczak, B.; Kalita-Kurzyńska, K.; Mołas, A.; Bzikowska-Jura, A. Feeding Strategies in Newborns and Infants During the COVID-19 Pandemic-Polish Cross-Sectional Study. *Int. J. Public Health* **2023**, *68*, 1605590.
88. Wako, W.G.; Wayessa, Z.; Fikrie, A. Effects of maternal education on early initiation and exclusive breastfeeding practices in sub-Saharan Africa: A secondary analysis of Demographic and Health Surveys from 2015 to 2019. *BMJ Open* **2022**, *12*, e054302.
89. Koziol-Kozakowska, A.; Stochel-Gaudyn, A.; Łuszczki, E. Evaluation of complementary feeding practices and mothers' nutritional knowledge in reference to current Polish recommendations. *J. Health Inequalities* **2022**, *8*, 145–154.
90. Titaley, C.R.; Dibley, M.J.; Ariawan, I.; Mu'asyaroh, A.; Paramashanti, B.A.; Alam, A.; Damayanti, R.; Do, T.T.; Ferguson, E.; Htet, M.K.; et al. The impact of a package of behaviour change interventions on breastfeeding practices in East Java Province, Indonesia. *Matern. Child Nutr.* **2022**, *18*, e13362. [\[PubMed\]](#)
91. Magnano San Lio, R.; Maugeri, A.; La Rosa, M.C.; Cianci, A.; Panella, M.; Giunta, G.; Agodi, A.; Barchitta, M. The Impact of Socio-Demographic Factors on Breastfeeding: Findings from the “Mamma & Bambino” Cohort. *Medicina* **2021**, *57*, 103. [\[CrossRef\]](#)
92. Lindsey, B.; Kampmann, B.; Jones, C.E. Maternal immunization as a strategy to decrease susceptibility to infection in newborn infants. *Curr. Opin. Infect. Dis.* **2013**, *26*, 248–253. [\[PubMed\]](#)
93. Kachikis, A.; Englund, J.A. Maternal immunisation: Optimising protection for the mother and infant. *J. Infect.* **2016**, *72*, S83–S90. [\[PubMed\]](#)
94. Bergin, N.; Murtagh, J.; Philip, R.K. Maternal Vaccination as an Essential Component of Life-Course Immunization and Its Contribution to Preventive Neonatology. *Int. J. Environ. Res. Public Health* **2018**, *15*, 847. [\[CrossRef\]](#)
95. Payakachat, N.; Hadden, K.B.; Ragland, D. Promoting Tdap immunization in pregnancy: Associations between maternal perceptions and vaccination rates. *Vaccine* **2016**, *34*, 179–186.
96. Moschese, V.; De Angelis, L.; Capogna, M.V.; Graziani, S.; Baglivo, F.; Pietropolli, A.; Miraglia Del Giudice, M.; Rizzo, C. Italian Society of Pediatric Allergy and Immunology (SIAIP) Vaccine Committee. Vaccine hesitancy and knowledge regarding maternal immunization among reproductive age women in central Italy: A cross sectional study. *Front. Glob. Womens Health* **2023**, *4*, 1237064.
97. Mose, A. Willingness to Receive COVID-19 Vaccine and Its Determinant Factors Among Lactating Mothers in Ethiopia: A Cross-Sectional Study. *Infect. Drug Resist.* **2021**, *14*, 4249–4259.
98. Maisonneuve, E.; Gerbier, E.; Tauqeer, F.; Pomar, L.; Favre, G.; Winterfeld, U.; Passier, A.; Oliver, A.; Baud, D.; Nordeng, H.; et al. Determinants of Vaccination and Willingness to Vaccinate against COVID-19 among Pregnant and Postpartum Women during the Third Wave of the Pandemic: A European Multinational Cross-Sectional Survey. *Viruses* **2023**, *15*, 1090. [\[CrossRef\]](#)
99. Comparcini, D.; Cicolini, G.; Totaro, M.; Governatori, L.; Pastore, F.; Miniscalco, D.; Flacco, M.E.; Cuscianna, E.; Tafuri, S.; Simonetti, V. Influenza vaccination hesitancy and related factors among pregnant and breastfeeding women: A cross-sectional study. *Hum. Vaccin. Immunother.* **2025**, *21*, 2450858. [\[CrossRef\]](#) [\[PubMed\]](#)
100. Goyal, R.C.; Banginwar, A.S.; Ziyo, F.; Toweir, A.A. Breastfeeding practices: Positioning, attachment (latch-on) and effective suckling—A hospital-based study in Libya. *J. Family Community Med.* **2011**, *18*, 74–79. [\[PubMed\]](#)
101. Brown, A.; Jordan, S. Impact of birth complications on breastfeeding duration: An internet survey. *J. Adv. Nurs.* **2013**, *69*, 828–839. [\[CrossRef\]](#)
102. Oakley, L.; Benova, L.; Macleod, D.; Lynch, C.A.; Campbell, O.M.R. Early breastfeeding practices: Descriptive analysis of recent Demographic and Health Surveys. *Matern. Child Nutr.* **2018**, *14*, e12535. [\[CrossRef\]](#) [\[PubMed\]](#)
103. Davis, A.M.B.; Sclafani, V. Birth Experiences, Breastfeeding, and the Mother-Child Relationship: Evidence from a Large Sample of Mothers. *Can. J. Nurs. Res.* **2022**, *54*, 518–529. [\[CrossRef\]](#)
104. Etti, M.; Calvert, A.; Galiza, E.; Lim, S.; Khalil, A.; Le Doare, K.; Heath, P.T. Maternal vaccination: A review of current evidence and recommendations. *Am. J. Obstet. Gynecol.* **2022**, *226*, 459–474. [\[CrossRef\]](#)
105. Lagousi, T.; Gkentzi, D.; Geropeppa, M.; Tsagkli, P.; Spoulou, V. Protecting the offspring, the gift of maternal immunization: Current status and future perspectives. *Vaccines* **2022**, *10*, 1953. [\[CrossRef\]](#)

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.